Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.84 |
| ▸ | POLB | P06746 | 3/20 | 0.84 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.84 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.84 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.84 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.84 |
| ▸ | TOP2A | P11388 | 4/20 | 0.56 |
| ▸ | TOP2B | Q02880 | 4/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orbifloxacin SCHEMBL9374152 | 1.00 | MEN1 (1.00) | MEN1KMT2AKCNH2POLBCACNA1F | |
| Orbifloxacin SCHEMBL29420860 | 1.00 | MEN1 (1.00) | MEN1KMT2AKCNH2POLBCACNA1F | |
| SCHEMBL10584006 | 0.93 | MEN1 (0.86) | MEN1KMT2AKCNH2POLBCACNA1F | |
| SCHEMBL10584011 | 0.93 | MEN1 (0.86) | MEN1KMT2AKCNH2POLBCACNA1F | |
| Sparfloxacin SCHEMBL1387460 | 0.92 | KCNH2 (1.00) | MEN1KMT2AKCNH2POLBCACNA1F | |
| Sparfloxacin SCHEMBL2637186 | 0.92 | KCNH2 (1.00) | MEN1KMT2AKCNH2POLBCACNA1F | |
| Sparfloxacin SCHEMBL41311 | 0.92 | KCNH2 (1.00) | MEN1KMT2AKCNH2POLBCACNA1F | |
| Sparfloxacin SCHEMBL29365159 | 0.92 | KCNH2 (1.00) | MEN1KMT2AKCNH2POLBCACNA1F | |
| Sparfloxacin SCHEMBL9368141 | 0.91 | KCNH2 (0.98) | MEN1KMT2AKCNH2POLBCACNA1F | |
| Sparfloxacin SCHEMBL28087316 | 0.91 | KCNH2 (0.98) | MEN1KMT2AKCNH2POLBCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2582 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2026-05-12 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| US-12350281-B2 | Long-acting injectable formulations and use thereof | DECHRA VETERINARY PRODUCTS, LLC (US) | 2025-07-08 | — | — | US | claimed |
| EP-4554627-A1 | INHALABLE FORMULATION FOR USE IN THE TREATMENT OF BACTERIAL LUNG INFECTIONS | Solmic Biotech GmbH (DE) | 2025-05-21 | — | — | EP | claimed |
| US-20250144088-A1 | INHALABLE FORMULATION FOR USE IN THE TREATMENT OF BACTERIAL LUNG INFECTIONS | Solmic Biotech GmbH (DE) | 2025-05-08 | — | — | US | claimed |
| WO-2025080590-A1 | CO-CRYSTALLIZATION OF ACTIVES WITH SACCHARIDE-BASED MOLECULAR FRAMEWORKS | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2025-04-17 | — | — | WO | claimed |
| US-20060122159-A1 | Pharmaceutical formulation | INTERVET INC. | 2006-06-08 | — | — | US | claimed |
| EP-1656143-A2 | NOVEL USE OF QUINOLONE ANTIBIOTICS | Bayer HealthCare AG (DE) | 2006-05-17 | — | — | EP | claimed |
| WO-2006020689-A1 | PHARMACEUTICAL FORMULATION COMPRISING AN ANTIBIOTIC, A TRIAZOLE AND A CORTICOSTEROID | SCHERING-PLOUGH LTD. (CH) | 2006-02-23 | — | — | WO | claimed |
| CN-1722956-A | Oral veterinary drug delivery system and/or feed additive delivery system, method for the production thereof and use thereof | ANNAMARIA SZOKE (HU) | 2006-01-18 | — | — | CN | claimed |
| EP-1560502-A1 | ORAL VETERINARY DRUG DELIVERY SYSTEM AND/OR FEED ADDITIVE DELIVERY SYSTEM, PROCESS FOR THE PREPARATION AND USE THEREOF | Szoke, Annamaria (HU) | 2005-08-10 | — | — | EP | claimed |
| WO-2005018641-A2 | NOVEL USE OF QUINOLONE ANTIBIOTICS | BAYER HEALTHCARE AG (DE) | 2005-03-03 | — | — | WO | claimed |
| WO-2004039172-A1 | ORAL VETERINARY DRUG DELIVERY SYSTEM AND/OR FEED ADDITIVE DELIVERY SYSTEM, PROCESS FOR THE PREPARATION AND USE THEREOF | SZOKE ANNAMARIA (HU) | 2004-05-13 | — | — | WO | claimed |
| US-6514492-B1 | Taste masking of oral quinolone liquid preparations using ion exchange resins | SCHERING-PLOUGH VETERINARY CORPORATION | 2003-02-04 | — | — | US | claimed |
| EP-1200129-A1 | TASTE MASKING OF ORAL QUINOLONE LIQUID PREPARATIONS USING ION EXCHANGE RESINS | SCHERING-PLOUGH LTD. (CH) | 2002-05-02 | — | — | EP | claimed |
| WO-2001005431-A1 | TASTE MASKING OF ORAL QUINOLONE LIQUID PREPARATIONS USING ION EXCHANGE RESINS | SCHERING-PLOUGH LTD. (CH) | 2001-01-25 | — | — | WO | claimed |